255 reports of this reaction
2.8% of all FLECAINIDE ACETATE reports
#4 most reported adverse reaction
DIZZINESS is the #4 most commonly reported adverse reaction for FLECAINIDE ACETATE, manufactured by ANI Pharmaceuticals, Inc.. There are 255 FDA adverse event reports linking FLECAINIDE ACETATE to DIZZINESS. This represents approximately 2.8% of all 9,204 adverse event reports for this drug.
Patients taking FLECAINIDE ACETATE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for FLECAINIDE ACETATE, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for FLECAINIDE ACETATE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 255 FDA reports for FLECAINIDE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 2.8% of all adverse event reports for FLECAINIDE ACETATE, making it a notable side effect.
If you experience dizziness while taking FLECAINIDE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.